

# Index

- A Fibers, 14–15, 45, 83–85
  - see also* Peripheral Nerve
- Absorption
  - and toxicity, 95–105, Table 31, Table 32
  - blood levels, 95–109,
    - Figure 5–1
  - dosage, 95, 100–102
  - drug profile, 95, Table 32
  - effects of
    - vasoconstrictors, 95, 103–104
  - function of total dose, 100–102
  - muscle, 97–100
  - site of administration, 95–100
    - deltoid, 98, Table 32
    - intercostal, 95–96, Table 32
    - peridural space, 95–97, Table 32
    - subarachnoid space, 95–97
    - trachea, 99–100
    - vastus lateralis, 98, Table 32
  - vascularity of injection
    - site, 99–100
- Acidosis
  - and convulsive threshold, 127–128
  - and tachyphylaxis, 88–89
- Action Potential, 19–35, 41–47
  - and ph, 29–33
  - conduction block, 23–28
  - effect of local anesthetics, 24–39
  - generation of, 19–23
- Adenosine Triphosphate (ATP), 23, 33–34
- Adverse Drug Reactions
  - see* Allergic Responses and Toxicity
- Allergic Responses
  - and amide-derivatives, 3, 10–11 142–143
  - and ester-derivatives, 3, 10
  - and local anesthetic agents, 142–143
  - and para-amino-benzoic acid derivatives, 3, 10–11, 142–143
  - and preservatives 143, 147
  - testing for, 143
  - treatment for, 145–148
- Amide-Linked Local Anesthetics, 3, 5, 9, 10
  - allergy, 3, 10–11, 142–143
  - and fetal brain, 113

- and fetal liver, 113
- and fetal uptake and protein-binding, 112–113
- and liver blood flow, 115
- and liver disease, 115
- excretion, 119–120
- metabolism, 114–119
- structure, Table 1
- Amines-Secondary, 5, Table 1
- Amines-Tertiary, 5, Table 1
- Amino-Amides, 5, Table 1
- Amino-Esters, 4, Table 1
- Amygdala
  - EEG changes, 123–124
- Anesthesia, Infiltration
  - see* Infiltration Anesthesia
- Anesthesia, Intravenous
  - see* Intravascular Infiltration
- Anesthesia Peridural
  - see* Epidural Anesthesia
- Anesthesia, Regional
  - see* Regional Anesthesia
- Anesthesia, Spinal
  - see* Spinal Anesthesia
- Anesthesia, Topical
  - see* Topical Anesthesia
- Anti-Arrhythmic Effects
  - see* Cardiac Effects of Local Anesthetics
- Anti-Convulsant Activity, 124–130
  - see also* Convulsive Threshold
  - and blood levels, 130
  - and depression of hyperexcitable cortical neurons, 130
  - and penicillin-induced convulsions, 129
- Autonomic Fibers
  - and CM, 83–84
  - and differential block, 83–84
- Axillary Block, 72–73
- Axolemma, Composition
  - see also* Nerve, 15–17
- Axon, *see* Nerve
- B Fibers, 14–15, 45
  - see also* Peripheral Nerve
- Barbiturates
  - as anticonvulsants, 128–129
- Base-Local Anesthetic dissociation, 29–33
- Benzocaine, 2–5
  - structure, 4, Table 1
  - synthesis, 2
  - topical anesthesia, 2
  - toxicity, 2
  - uses, 4
- Benzoic Acid Derivatives, 2–5, 8–11
- Bier, 2
- Bier Block
  - see* Intravascular Infiltration
- Bile
  - excretion into, 119–120
- Biotoxin, 6
  - see also* Tetrodotoxin and Saxitoxin, 6
- Blocking Rate
  - see also* Onset
  - and carbonated solution, 32–33, 73
  - and pH, 29–32, 48
- Blood Brain Barrier
  - local anesthetics, 123
- Blood Level, 95–113
  - and toxicity, 95–105
  - and vasoconstrictor, 103–106
  - arterial versus venous, 107, 111–112,
  - convulsant, 125–128
  - decay curve, 106–109
  - intravenous regional, 68
  - as a function of injection site, 96–97 (Fig. 5-1)
- Brachial Plexus Block
  - see* Major Nerve Blocks
- Braun, 2
- Bupivacaine
  - antiarrhythmic activity, 133
  - arterio-venous difference of blood levels, 111
  - duration of action, 58–59
  - epidural anesthesia, 80–85
  - excretion, 119
  - half-life, 109

- infiltration anesthesia, 62–63
  - intravascular infiltration, 67–68
  - lipid solubility and epidural administration, 104
  - major nerve blocks, 70–75
  - metabolism, 115–118
  - minor nerve blocks, 69–70
  - onset of action, 58
  - partition coefficient, 7
  - peak blood level-vasoconstrictor, 103
  - placental transfer, 112
  - potency, 7
  - protein-binding, 7, 107
  - structure, 5, Table 1
  - toxicity, 125–129
  - vasodilation, 104, 135
  - with epinephrine, 63, 104
- C Fibers, 14–15, 46, 83–84**  
*see also* Peripheral Nerve
- Calcium**
- and action in excitation, 26–29
  - and anesthetic potency, 26–28, Table 5
  - and local anesthetic interaction, 26–28, Table 5
  - phospholipid complexes, 28
- Carbocaine, *see* Mepivacaine**
- Cardiac Effects of Local Anesthetics, 131–133**
- and action potential duration, 131
  - and automaticity, 132
  - and cardiac arrhythmias, 132
  - and conduction velocity, 132
  - and effective refractory period, 131
  - and inhibition of sodium conductance, 132
  - and ion fluxes, 132
  - and negative inotropic effects, 133
  - and phase 0 depolarization (rate of rise), 132
  - and phase 4 depolarization, 131
  - and resting potential, 132
- Cardiovascular Collapse**
- signs and symptoms of, 131, 136, 146–147
- Cardiovascular Effects of Regional Block**
- epidural administration, 136–139
  - spinal administration, 137–138
- Categories of Regional Anesthetic Procedures, 57, Table 15**
- Cation**
- base-cation ratio, 29–33
  - dissociation, 29–31
  - dissociation equation, 30
  - local anesthetic, 29–33, 37–38
- Caudal Anesthesia**
- for pelvic and perineal surgery, 75
- Central Nervous System Effects, 123–130**
- anticonvulsant, 129–130
- Central Neural Blockade, 75–89**
- Chemical Classification of Local Anesthetics, 4–6, Table 1**
- Chemical Structure, 4–11, Table 1**
- and potency, 9
  - and toxicity, 9
- Chloroprocaine**
- and plasma cholinesterase, 105–114
  - epidural anesthesia, 20
  - excretion, 119
  - intravascular infiltration, 67
  - metabolism, 8, 105, 114
  - structure, 5, Table 1
  - synthesis, 2
  - thrombophlebitis, 67
  - toxicity, 9, 141–143
  - vasodilation, 106
- Citanest, *see* Prilocaine**
- CM (Minimum Anesthetic Concentration), 41, 43–46**
- Cocaine**
- absorption, 1, 100
  - addiction, 2
  - anticonvulsant, 129–130
  - excretion, 119
  - metabolism, 119
  - structure, Table 1

- sympathomimetic action, 106, 135
  - synthesis, 1
  - topical anesthesia, 90–92
  - toxicity, 2
  - vasoconstriction, 106, 135
- Conductance
  - calcium, 26–29
  - local anesthetic effect on, 25–29
  - membrane, 22–23, 25–29
  - potassium, 19–23, 25–29
  - sodium, 19–23, 25–29
- Conduction Velocity
  - autonomic fibers, 83–84
  - slowing by local anesthetics, 25–28
- Convulsive Threshold, 123–129
  - acid-base status, 127, 128
  - and barbiturates, 128
  - and diazepam, 128
  - and nitrous oxide, 128
  - and prevention, 146
  - and resuscitation, 146
  - anesthetic blood level, 125
  - concomitant agents and depression, 128
  - concomitant use of other agents, 128
  - intrinsic anesthetic potency, 125
  - pre-convulsive patterns, 126
  - rate of administration, 126
- Delta Fibers, 83–85
- Depolarization
  - and ionic fluxes, 19–23
  - and voltage changes, 19–23
- Depolarization and Local Anesthetics, 25–29
- Diazepam, 128–129
- Dibucaine, 47, 90
- Diethylamino ethanol, 3, 114, 119
- Differential Block, 83–84
- Diffusion Barriers
  - and potency, 13, 30–32, 38, 45–46
  - and rate of block, 13, 30–32, 38, 45–46, 72–73
  - blood-brain, 123
  - connective tissue, 13, 30–32, 38, 72–73
  - dura, 46
- Dinitrophenol, 23
- Disposition Kinetics, *see* Kinetics
- Dissociation, 29–33
- Distribution of Local Anesthetic Agents, 106–113
  - and protein binding, 109, 113
- Dorsal Root Ganglia, 76
- Duration of Action, 48–51
  - in vivo models, 51
- Duration of Analgesia
  - see* By Individual Blocks
- Dyclonine
  - topical anesthesia, 90
- Einhorn, 2
- Electrochemistry, 21
- Electrophysiology, 19–23
- Endoneurium, 13 (Fig. 2-1)
- Epidural Anesthesia, 75–85
  - 2-segment regression, 82
  - age and height, 79
  - anesthetic agent, 80
  - arteriosclerosis, 79
  - factors influencing quality, 77
  - mechanism, 75
  - onset time, 80–81
  - patient position, 78
  - pregnancy, 79
  - site of action, 77
  - site of injection, 78
  - speed of injection, 78
  - total duration, 82
  - volume and concentration of local anesthetic, 80
- Epidural Space, 75
- Epilepsy
  - treatment with local anesthetics, 130

- Epinephrine  
 absorption of local anesthetics  
   from epidural space, 104  
 cardiovascular effects following  
   epidural block, 138–139  
 effects on pharmacokinetics, 103  
 infiltration anesthesia, 63  
 major nerve blocks, 74  
 minor nerve blocks, 70  
 pulpal anesthesia, 64
- Epineurium, 13 (Fig. 2-1)
- Erythrocyte Membrane  
 and resistance to hemolysis, 37
- Esmarch Bandage  
*see* Intravascular Infiltration
- Ester Compounds  
 metabolism, 114  
*see* Procaine, Chlorprocaine,  
 Tetracaine
- Etidocaine  
 absorption, 100–102  
 and protein-binding, 107  
 arterio-venous difference, 111–112  
 blood levels, 105  
 cardiovascular effects following  
   epidural block, 138  
 duration of action, 17–18  
 epidural anesthesia, 80, 85  
 half-life, 109  
 intravascular infiltration, 67–68  
 lipid solubility, 17–18  
 lipid solubility and epidural  
   administration, 104  
 major nerve blocks, 73  
 metabolism, 115–118  
 minor nerve blocks, 69–70  
 onset of action, 17–18, 73  
 peak blood level, 102  
 peak blood level-vasoconstrictor,  
   103–104  
 placental transfer, 112–113  
 potency, 8  
 protein-binding, 17–18  
 structure, 5  
   vasodilation, 104
- Excretion, 119–121
- Fetal blood levels, 112–113
- Fiber  
*see* Nerve Fiber
- Flooding Technique  
 brachial plexus blocks, 72
- Gaedcke, 1
- Gate  
 membrane, 37
- Grand Mal Seizures  
 and local anesthetics, 130
- Guanidine-Type Structures, 5
- Half-Life of Anesthetic, 108–109
- Halstead, 2
- Historical Notes, 1–3
- Hydrophilicity, 7
- Hypersensitivity  
*see* Allergic Responses
- Hypotension  
 and spinal or epidural anesthesia,  
 137
- Impulse  
*see* Action Potential
- In Vitro Experimental Models,  
 41–48
- In Vivo Animal Models, 48–55
- Indirect Effect of Local Anesthetic  
 Agents, 136–141
- Infiltration Anesthesia, 62–69  
 extravascular, 62–65  
 intravascular, 62–69  
 intravascular drug-related  
   considerations, 67  
 intravascular pharmacodynamic  
   considerations, 68  
 intravascular technical  
   considerations, 65

- Intercostal Nerve Blocks  
*see* Major Nerve Blocks, 72
- Interscalene Block, 72
- Intervertebral Foramina, 76
- Intravascular Infiltration  
 concentration of local anesthetic, 68  
 Esmarch bandage, 65  
 intermittent tourniquet release, 66  
 preinjection exsanguination and ischemia, 66  
 site of action, 69  
 thrombophlebitis, 65  
 volume of local anesthetic, 68
- Ionic Fluxes, 22–26  
 and local anesthetics, 25–26  
 during depolarization, 22–23
- Ionic Gradients  
 at rest, 21–22
- Ischemia  
 and intravascular infiltration, 66  
 and pain, 66
- Kidney  
*see* Excretion
- Kinetics, 107–109  
 alpha phase, 108  
 beta phase, 108  
 gamma phase, 108
- Koller, 1
- Lidocaine  
 absorption, 101  
 anti-arrhythmic activity, 131–132  
 anti-convulsant activity, 129–130  
 arterio-venous difference, 111–112  
 blood levels, 105  
 cardiovascular effects following epidural block, 138  
 dental use, 64–65  
 duration of action, 58  
 epidural anesthesia, 80  
 epinephrine, 63  
 excretion, 119–121  
 half-life, 108  
 in liver, 109  
 infiltration anesthesia, 62  
 intravascular infiltration, 67–68  
 major nerve blocks, 73  
 metabolism, 115–117  
 metabolites, 118  
 minor nerve blocks, 69–70  
 onset of action, 58  
 peak blood level, 102  
 peak blood level-vasoconstrictor, 103  
 pulpal anesthesia, 64  
 spinal anesthesia, 87–88  
 structure, 5, 9, Table 1  
 tissue distribution, 109–111  
 topical anesthesia, 90  
 toxicity, 125  
 vasodilation, 135
- Lipid Solubility, 17–18
- Lipophilicity, 7
- Liver  
 excretion by, 119–120  
 metabolism in, 115–118
- Local Anesthesia  
 definition, 1  
 history, 1–2
- Local Anesthetic  
 active form, 29–33  
 and allergic responses, 142–143  
 and anaphylaxis, 142–143  
 and antibacterial activity, 141  
 and anticholinergic effects, 141  
 and antihistaminic effects, 141  
 and blood gas tensions, 140  
 and blood pressure, 136  
 and cellular metabolism, 33  
 and CO<sub>2</sub> potentiation, 32  
 and drug interactions, 142  
 and effects on capacitance vessels, 134  
 and ganglionic blockage, 141  
 and histological changes in skeletal muscle, 144–145

and increased serum CPK following intramuscular injection, 145

and ionic flux, 25–26

and leukocyte aggregation, 144

and lipid solubility, 17

and local tissue toxicity, 143–144

and neuromuscular blocking agents, 141–142

and other drugs with similar metabolic pathways, 142

and preservatives in solution, 144

and protein-binding, 17, 106–109

and rapid axonal transport, 144

and red blood cell hemolysis, 143–144

and systemic toxicity, 145

and vasoconstriction, 134

and vasodilation, 135

anti-convulsive action, 129

biphasic peripheral vascular effects, 135

calcium interaction, 26–28, 135

calcium and sodium interaction, 28, 34

cardiodepressant activity with concomitant agents, 136

cardiovascular effects following epidural block, 139

cardiovascular effects following sciatic-femoral block, 140

cardiovascular effects in presence of hypovolemia, 139

chemical classification, 4, Table 1

classification by duration, 48, 51

classification by potency, 46–47

classification by site of action, 37

commercial preparations, Table 1

definition, 1

degradation-toxicity relationships, 8

diffusion rates, 13

dissociation, 29–33

effects on respiration, 140

electrophysiological actions, 23–25

frequency of adverse experiences, 146

history, 1–2

maternal-fetal distribution, 113

mechanism of action, 23–26, 28

metabolism, 114–119

onset, 13

ph, 30–31, 36

pharmacological properties, 13, 17, 19

potency and calcium displacement, 28

preclinical aspects, 41

receptor sites, 34–55

    external receptor site, 35

    internal receptor site, 35

site of action, 32, 33, 37

skeletal muscle uptake, 111

structure-activity relationships, 6, 9, 37

toxicity, 2, 123, 129, 131, 148

*see also* Toxicity

Lofgren, 2

Major Nerve Block, 70–74

    brachial plexus block, 70–72

    epinephrine effects, 74

    intercostal nerve blocks, 70–72

    onset time, 73

    variability in duration, 74

#### Marcaine

*see* Bupivacaine

#### Maternal and Fetal Tissue

Distribution of Local Anesthetics, 113

#### Membrane Expansion Theory, 36–37

#### Membrane Receptor Site, 34–35

external, 35

internal, 35

#### Mepivacaine 32–33, 73, 127–128

antiarrhythmic activity, 133

blood levels, 105

dental use, 64–65

epidural anesthesia, 80

excretion, 119

- half-life, 108
- infiltration anesthesia, 62
- intravascular infiltration, 67–68
- major nerve blocks, 73
- metabolism, 117
- minor nerve blocks, 69–70
- peak blood level-vasoconstrictor, 103
- placental transfer, 112
- structure, 5, Table 1
- synthesis, 5
- toxicity, 125
- vasodilation, 135
- Metabolic Inhibitors, 33
- Metabolism
  - and amide-derivatives, 9, 115–116
  - and ester-derivatives, 9, 114
  - see also* Individual Local Anesthetic Agents
- Methemoglobinemia, 9, 119
- Methylparaben, 62, 143, 147
- Minimum Anesthetic Concentration
  - see* (CM)
- Minor Nerve Blocks, 69–70
- Mode of Action
  - active structure, 29–33
  - calcium interaction, 26–28, 135
  - effect of ATP, 23
  - sodium flux inhibition, 25–26
- Monoethylglycine Xylidide, 116
- Moreno Y Maiz, 1
- Myelin
  - function, 14–15
  - molecular configuration, 15
  - node of ranvier, 14–15
  - Schwann cell, 14–15
  - structure, 14–15
- Myelinated Nerve
  - A and B fibers, 14–15
  - anatomy, 14–15
- Nerve
  - and ionic concentration, 20
  - and sodium pump, 23
  - axolemma, 15
  - axon, 13
  - axoplasm, 15
  - excitation process, 22–23
  - membrane activation, 22
  - membrane electrochemistry, 20
  - membrane electrophysiology, 19–23
  - membrane models, 15
  - Nodes of Ranvier, 15
  - peripheral, 13
  - sheath, 13–15
- Nerve Block
  - action potential, 23–39
  - active structure, 29–33
  - tachyphylaxis, 88–89
- Nerve Fibers
  - A fibers, 45, 83–84
  - B fibers, 45, 83–84
  - C fibers, 45, 83–84
- Nesacaine
  - see* Chloroprocaine
- Neuromuscular Block
  - and succinylcholine interaction, 142
- Niemann, 1
- Node of Ranvier, 14–15
- Non-Ionizable Local Anesthetic
  - N-butanol, 33
- Norepinephrine
  - absorption of local anesthetics from epidural space, 104
- Novocaine
  - see* Procaine
- Nupercaine
  - see* Dibucaine
- Onset, 47–53
  - and lipid solubility, 47
  - and  $pK_a$ , 47
  - duration and potency compared, 47
  - in vivo* models, 50
- Pain
  - fibers conducting, 83–84
  - tourniquet ischemia, 66
- Para Aminobenzoic Acid Esters
  - see* Procaine, Chloroprocaine, and Tetracaine



- Para-Aminobenzoic Acid, 10  
 Paravertebral Nerve Trunks, 76  
 Partition Coefficient, 7  
 Peak Blood Level  
   function of total dose, 102  
 Perineurium, 13 (Fig. 2-1)  
 Peripheral Nerve  
   anatomy, 13-18  
   physiology, 19-23  
 Peripheral Nerve Blockade, 69-70  
   major nerve blocks, 70-74  
   minor nerve blocks, 69-70  
 Peripheral Vascular Effects, 134  
 Petit Mal Seizures  
   and local anesthetics, 130  
 pH  
   and base-cation ratio, 29-33  
   and carbon dioxide, 32, 33, 127, 128  
   and local anesthetics, 29-33  
   and potency, 29-33  
   and tachyphylaxis, 88-89  
 Pharmacokinetics, 95  
 Phenylephrine, 83  
   absorption of local anesthetics  
   from epidural space, 104  
 Phospholipids  
   CA<sup>++</sup> interaction  
   complex formation, 28  
   in nerve membrane, 15-17  
 pK<sub>a</sub>, 29-30  
 Placental Transfer, 111-113  
   fetal blood levels, 111-113  
   fetal-maternal gradients, 111-113  
   protein-binding, 113  
 Plasma Cholinesterase  
   *see* Pseudocholinesterase  
 Plasma/Erythrocyte Concentration  
   and protein-binding, 111  
 Pontocaine  
   *see* Tetracaine  
 Potassium  
   and local anesthetics, 20-21  
   and resting membrane potential,  
   20-21  
   pump, 23  
   Potassium Flux  
     and tetraethyl ammonium, 26  
 Potency, 31-32, 36, 41, 44, 49  
   and base concentration, 31-32  
   and carbon dioxide, 32-33  
   and cation concentration, 31-32  
   and diffusion barriers, 13, 30-32,  
   38-45  
   and nerve sheath, 46  
   and onset, 47  
   and pH, 36  
   and rate of stimulation, 45  
   and sodium concentration, 25  
   and type of nerve preparation, 45  
   in vitro and in vivo, 49  
   intrinsic, 46  
   topical, 50  
 Prilocaine  
   absorption, 101-102  
   and poor protein-binding, 107  
   and toluidine product, 118  
   antiarrhythmic activity, 133  
   arterio-venous difference, 111  
   blood levels, 105  
   dental use, 64-65  
   epidural anesthesia, 80, 104  
   excretion, 119  
   half-life, 108  
   in lung, 109  
   infiltration anesthesia, 62  
   intravascular infiltration, 67-68  
   metabolism, 115-117  
   metabolites and methemoglobin-  
   emia, 9, 119  
   minor nerve blocks, 69  
   peak blood level, 102  
   peak blood level-vasoconstrictor,  
   103  
   placental transfer, 112  
   rapid tissue redistribution, 104  
   structure, 5, 9, Table 1  
   topical anesthesia, 90  
   toxicity, 5, 9, 119  
   vasodilation, 135  
 Procaine  
   allergy, 2, 11

- and plasma cholinesterase, 105
- anti-convulsant activity, 130
- epidural anesthesia, 80
- esterase, 9–11
- in vitro potency, 7
- in vivo potency, 7
- infiltration anesthesia, 62
- intravascular infiltration, 67
- metabolism, 114
- potency, 7
- pulpal anesthesia, 64
- structure, 4, Table 1
- synthesis, 2
- tissue distribution, 109
- toxicity, 9, 125
- uses, 2, 4
- vasodilation, 106
- Protein-Binding, 7, 17–18, 106–113
  - and transplacental drug transfer, 113
- Pseudocholinesterase
  - see also* Cholinesterase
  - metabolism of ester compounds, 9, 59, 105, 114
- Puffer Fish Toxin, *see* Tetrodotoxin
- Pulpal Anesthesia, 63–64
  
- Quaternary Ammonium Compounds
  - site of action, 35
  
- Ranvier
  - Node of, 15
- Redistribution
  - of local anesthetic, 106–111
- Regional Anesthesia
  - classification, 57, 93, Table 15
  - onset and duration, 93–94
- Regional Block
  - see also* Regional Anesthesia
  - and decreased hepatic blood flow, 138
  - and decreased renal plasma flow, 138
  - cardiovascular effects, 137–138
- Resting Potential, 19–23
  - ionic gradients, 20–21
  - metabolic inhibitors, 23
- Ritsert, 2
  
- Saxitoxin
  - and ionic flux, 26, 28
  - derivation, 5
  - spinal anesthesia, 86
  - structure, 5–6
- Schwann Cell, 14–15
- Secondary System Effects
  - see* Indirect Effect of Local Anesthetics
- Seizure Threshold
  - see* Convulsive Threshold
- Sheath
  - nerve, 13–14
- Shellfish Poisoning
  - see* Saxitoxin
- Site of Action of Local Anesthetic Agents, 37, Table 7
  - ionic channels, 33–39
- Site of Injection, 95
- Skin
  - diffusion barrier, 89–94
- Sodium
  - and action potential, 20–23
  - and interaction with local anesthetics, 28–34
  - conductance, 20–23
  - interaction with calcium, 26–28
- Sodium Pump, 23, 33–34
- Spinal Anesthesia, 85–89
  - anesthetic factors, 85–87
  - comparison with epidural, 85–86
  - factors affecting, 87
  - patient factors, 87
  - tachyphylaxis, 89
  - technical factors, 88
- Spinal Cord, 77
- Structure Activity Relationships, 6–10
- Subarachnoid Block
  - see* Spinal Anesthesia
- Supraclavicular Block, 72
- Sympathetic Nerve Block, 84
- Systemic Effects, 123–148

- Systemic Effects—Convulsions  
*see* Convulsive Threshold
- Systemic Toxicity  
and inadvertent intravascular injection, 148  
local anesthetic agents, 145  
treatment, 145
- Tachyphylaxis, 88–89
- Tetracaine  
absorption, 100  
and plasma cholinesterase, 105  
epidural anesthesia, 80  
excretion, 119  
in vitro potency, 7  
in vivo potency, 7  
major nerve blocks, 73  
metabolism, 8, 114  
minor nerve blocks, 69  
potency, 7  
spinal anesthesia, 85–88  
structure, 4, Table 1  
synthesis, 2  
topical anesthesia, 90  
toxicity, 8  
uses, 4  
vasodilation, 106, 135
- Tetraethyl Ammonium  
and ionic flux, 26
- Tetrodotoxin  
and ionic flux, 26  
derivation, 5–6  
spinal anesthesia, 86  
structure, 5–6
- Tissue Distribution of Local Anesthetics  
and tissue perfusion, 109
- Topical Anesthesia, 89–92  
cations, 92  
colloids, 92  
detergents, 92  
forms of application, 92  
intact skin, 92  
mucous membranes, 92  
site of application, 90  
spreading agents, 92
- Tourniquet  
*see* Intravascular Infiltration
- Toxicity  
and rate of degradation, 8  
circumoral and tongue numbness, 123  
CNS depression, 124  
convulsions, 125  
dizziness, 124  
EEG changes, 124  
lightheadedness, 124  
twitching and tremors, 124
- Treatment of Toxic Effects  
adequate respiratory exchange, 145  
and CNS depressant drugs, 145  
and neuromuscular blocking agents, 145  
prevention of toxic effects, 146
- Unit Membrane  
definition, 15
- Valium, *see* Diazepam
- Variations In Anesthetic Activity  
blood loss, 59  
factors, 57–58  
liver dysfunction, 59  
physical and clinical status of patient, 59  
pseudocholinesterase, 59  
solution composition, 60  
vasoconstrictors, 61
- Vasoconstrictor Agents, 51  
*see also* Epinephrine and Phenylephrine  
and epidural administration, 104  
effects on pharmacokinetics and blood levels, 103–104
- Ventral Spinal Roots, 76
- Voltage Clamp  
ionic flux, 28
- Volume of Distribution, 108–109
- Xylidine Derivatives  
*see* Lidocaine, Mepivacaine, Prilocaine
- Xylocaine  
*see* Lidocaine